Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma.

@article{Shi2015ResultsFA,
  title={Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma.},
  author={Yuankai Shi and Mei-ling Dong and Xiaonan Hong and Wen-yi Zhang and Jifeng Feng and J Zhu and Liping Yu and Xiao-yan Ke and Hui-qiang Huang and Zhixiang Shen and Yun Fan and Wei Li and Xin Qing Zhao and Junyuan Qi and He Huang and Dao-Bin Zhou and Zhiqiang Ning and Xianping Lu},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2015},
  volume={26 8},
  pages={
          1766-71
        }
}
BACKGROUND Chidamide is a novel benzamide type of subtype-selective histone deacetylase (HDAC) inhibitor with unique mechanisms of action compared with marketed HDAC inhibitors. This phase II study was to evaluate the efficacy and safety of chidamide in relapsed or refractory peripheral T-cell lymphoma (PTCL) in Chinese population. PATIENTS AND METHODS Patients with relapsed or refractory PTCL of different subtypes received chidamide of 30 mg orally twice per week. The primary end point was… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 45 CITATIONS

Current status and progress of lymphoma management in China

  • International Journal of Hematology
  • 2018
VIEW 6 EXCERPTS
CITES BACKGROUND

Therapeutic options in peripheral T cell lymphoma

  • Journal of Hematology & Oncology
  • 2016
VIEW 15 EXCERPTS
CITES RESULTS
HIGHLY INFLUENCED